In addition, the CRISPR/Cas9 and TXNIP gRNA method employed in this study may also be a potential strategy for knocking out TXNIP and preventing DR progression, as well as other microvascular complications of diabetes. This evidence concerns the gene TXNIP and diabetes mellitus.